[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Glaukos Corp (GKOS)

Glaukos Corp (GKOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,109,860
  • Shares Outstanding, K 58,527
  • Annual Sales, $ 507,440 K
  • Annual Income, $ -187,690 K
  • EBIT $ -87 M
  • EBITDA $ -47 M
  • 60-Month Beta 0.78
  • Price/Sales 13.94
  • Price/Cash Flow N/A
  • Price/Book 10.58

Options Overview Details

View History
  • Implied Volatility 64.29% (+0.58%)
  • Historical Volatility 36.35%
  • IV Percentile 86%
  • IV Rank 63.62%
  • IV High 79.27% on 04/25/25
  • IV Low 38.07% on 08/12/25
  • Expected Move (DTE 19) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 574
  • Open Int (30-Day) 1,297
  • Expected Range 121.48 to 121.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 5
  • High Estimate $-0.23
  • Low Estimate $-0.40
  • Prior Year $-0.22
  • Growth Rate Est. (year over year) -36.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.12 +18.96%
on 03/30/26
127.00 -4.35%
on 04/20/26
+16.25 (+15.44%)
since 03/24/26
3-Month
95.87 +26.71%
on 03/13/26
128.84 -5.71%
on 01/28/26
+1.50 (+1.25%)
since 01/23/26
52-Week
73.16 +66.05%
on 10/28/25
130.23 -6.72%
on 01/22/26
+26.05 (+27.30%)
since 04/24/25

Most Recent Stories

More News
Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 121.48 (+0.50%)
Glaukos Receives Permanent J-code for Epioxaâ„¢

New J-code for Epioxa â„¢ , J2789, set to become effective July 1, 2026

GKOS : 121.48 (+0.50%)
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

Conference Call and Webcast Scheduled for 1:30 p.m. PT

GKOS : 121.48 (+0.50%)
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced...

GKOS : 121.48 (+0.50%)
Glaukos Announces Commercial Availability of Epioxaâ„¢, a Transformative Innovation in Interventional Keratoconus Care

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease

GKOS : 121.48 (+0.50%)
Glaukos: Q4 Earnings Snapshot

Glaukos: Q4 Earnings Snapshot

GKOS : 121.48 (+0.50%)
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 121.48 (+0.50%)
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 121.48 (+0.50%)
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

Conference Call and Webcast Scheduled for 1:30 p.m. PT

GKOS : 121.48 (+0.50%)
Stock Indexes Settle Lower on Tech Weakness

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.53%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.07%. March...

MSTR : 171.02 (-0.84%)
GOOGL : 344.40 (+1.63%)
MPC : 224.14 (+1.37%)
GLXY : 26.00 (-1.05%)
RIVN : 16.52 (-2.54%)
ABNB : 142.82 (+0.67%)
COIN : 199.77 (+0.93%)
TGTX : 36.62 (-0.81%)
OXY : 57.12 (-1.23%)
TSLA : 376.30 (+0.69%)
^BTCUSD : 78,076.22 (+0.42%)
SPY : 713.94 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an...

See More

Key Turning Points

3rd Resistance Point 126.09
2nd Resistance Point 124.18
1st Resistance Point 122.83
Last Price 121.48
1st Support Level 119.58
2nd Support Level 117.67
3rd Support Level 116.32

See More

52-Week High 130.23
Last Price 121.48
Fibonacci 61.8% 108.43
Fibonacci 50% 101.69
Fibonacci 38.2% 94.96
52-Week Low 73.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.